logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 16 of 16 Items
Showing 1 - 16 of 16 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Host preference and human blood index of Phlebotomus orientalis, an exophilic sand fly vector of visceral leishmaniasis in eastern Sudan

Jibreel T, Khogali A, Jiménez M, Raiyed A, Dakein O,  et al.
2023-08-04 • Medical and Veterinary Entomology
2023-08-04 • Medical and Veterinary Entomology
Visceral leishmaniasis (VL, kala azar), caused by Leishmania donovani, transmitted by Phlebotomus orientalis, is a serious systemic disease that causes high morbidity and mortality rates...
Journal Article
|
Research

The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001–2018

Naylor-Leyland G, Collin SM, Gatluak F, den Boer ML, Alves F,  et al.
2022-08-18 • PLOS Neglected Tropical Diseases
2022-08-18 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral Leishmaniasis (VL) is endemic in South Sudan, manifesting periodically in major outbreaks. Provision of treatment during endemic periods and as an emergency respo...
Journal Article
|
Research

"Kala-Azar is a Dishonest Disease": Community Perspectives on Access Barriers to Visceral Leishmaniasis (Kala-Azar) Diagnosis and Care in Southern Gadarif, Sudan

Sunyoto T, Adam GK, Atia AM, Hamid Y, Babiker RA,  et al.
2018-02-22 • American Journal of Tropical Medicine and Hygiene
2018-02-22 • American Journal of Tropical Medicine and Hygiene
Early diagnosis and treatment is the principal strategy to control visceral leishmaniasis (VL), or kala-azar in East Africa. As VL strikes remote rural, sparsely populated areas, kala-az...
Journal Article
|
Research

Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia

Tekalign S, Adera C, den Boer ML, Miecha H, Zewde A,  et al.
2020-06-30 • Journal of Infection in Developing Countries
2020-06-30 • Journal of Infection in Developing Countries
Introduction: In three health care facilities in the Oromia region, the aim of this study is to report on 1) the number of VL cases registered over time (2013-2018) and 2) the clinical p...
Conference Material
|
Poster

Patient characteristics and treatment outcomes from MSF's cutaneous leishmaniasis programme in Pakistan: a retrospective cohort

Kamink SS, Masih B, Saleem A, Khan J, Masih S,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research
Journal Article
|
Research

Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study

Coulborn RM, Gebrehiwot TG, Schneider M, Gerstl S, Adera C,  et al.
2018-11-08 • PLOS Neglected Tropical Diseases
2018-11-08 • PLOS Neglected Tropical Diseases
Ethiopia bears a high burden of visceral leishmaniasis (VL). Early access to VL diagnosis and care improves clinical prognosis and reduces transmission from infected humans; however, sig...
Journal Article
|
Review

Towards the elimination of visceral leishmaniasis as a public health problem in East Africa: reflections on an enhanced control strategy and a call for action

Alvar J, den Boer ML, Dagne DA
2021-12-01 • Lancet Global Health
2021-12-01 • Lancet Global Health
East Africa is the world region most affected by visceral leishmaniasis, accounting for 45% of cases globally that were reported to WHO in 2018, with an annual incidence that is only sli...
Journal Article
|
Research

Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study

Sunyoto T, Potet J, den Boer ML, Ritmeijer KKD, Postigo JAR,  et al.
2019-05-01 • BMJ Open
2019-05-01 • BMJ Open
OBJECTIVES:
To understand stakeholders' perceptions of the access barriers to quality-assured diagnostics and medicines for leishmaniasis in the high-burden region of eastern Africa...
Journal Article
|
Commentary

Developments in the treatment of visceral leishmaniasis

den Boer ML, Alvar J, Davidson RN, Ritmeijer KKD, Balasegaram M
2009-08-27 • Expert Opinion on Emerging Drugs
2009-08-27 • Expert Opinion on Emerging Drugs
BACKGROUND: Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontine...
Journal Article
|
Research

Safety and effectiveness of short-course AmBisome in the treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a prospective cohort study in Bangladesh

den Boer ML, Das AK, Akhter F, Burza S, Ramesh V,  et al.
2018-03-15 • Clinical Infectious Diseases
2018-03-15 • Clinical Infectious Diseases
A safe and effective short-course treatment regimen for Post Kala Azar Dermal Leishmaniasis (PKDL) is considered essential for achieving and sustaining elimination of visceral leishmania...
Journal Article
|
Review

Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience

Alcoba G, Potet J, Vatrinet R, Singh SN, Nanclares C,  et al.
2022-03-01 • Toxicon: X
2022-03-01 • Toxicon: X
Snakebite envenoming is a public health concern in many countries affected by humanitarian crises. Its magnitude was recognized internationally but associations between snakebite peaks a...
Journal Article
|
Commentary

Control of visceral leishmaniasis in East Africa: fragile progress, new threats

Dahl EH, Hamdan M, Mabrouk L, Matendechero S, Mengistie TB,  et al.
2021-08-13 • BMJ Global Health
2021-08-13 • BMJ Global Health
SUMMARY BOX

• Significant progress has been made in reducing the global burden of visceral leishmaniasis, but new threats are on the horizon.
• Funding for elimination of ...
Journal Article
|
Research

Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy-A retrospective analysis

Kamink SS, Masih B, Ali N, Ullah A, Khan SJ,  et al.
2021-01-28 • PLOS Neglected Tropical Diseases
2021-01-28 • PLOS Neglected Tropical Diseases
BACKGROUND
Cutaneous leishmaniasis (CL) is a neglected tropical skin disease, caused by Leishmania protozoa. In Pakistan, where CL caused by L. tropica is highly endemic, therapy wi...
Journal Article
|
Research

Outdoor Residual Insecticide Spraying (ODRS), a new approach for the control of the exophilic vectors of human Visceral Leishmaniasis: Phlebotomus orientalis in East Africa

Elnaiem DA, Dakein O, Alawad AM, Alsharif B, Khogali A,  et al.
2020-10-20 • PLOS Neglected Tropical Diseases
2020-10-20 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL) due to Leishmania donovani is a neglected protozoan parasitic disease in humans, which is usually fatal if untreated. Phlebotomus orientalis, the predominant ...
Journal Article
|
Research

Epidemiological and molecular investigation of resurgent cutaneous leishmaniasis in Sudan

Collis S, el Safi S, Atia AM, Bhattacharya S, Hammad A,  et al.
2019-08-20 • International Journal of Infectious Diseases
2019-08-20 • International Journal of Infectious Diseases
OBJECTIVES:
Local health personnel have drawn attention to an apparent increase in incidence and severity of cutaneous leishmaniasis (CL) in Sudan. The objective of this study was t...
Journal Article
|
Case Report/Series

Hypokalaemia-induced rhabdomyolysis after treatment of post-kala-azar dermal leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh - A case report

Marking U, den Boer ML, Das AK, Ahmed EM, Rollason V,  et al.
2014-06-12 • PLOS Neglected Tropical Diseases
2014-06-12 • PLOS Neglected Tropical Diseases